All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-11-30T23:24:25.000Z

Thrombotic and hemorrhagic complications in MPN

By Oscar Williams, Lauren Lett
Featured
Chloé James
Jean-Jacques Kiladjian
John Mascarenhas
Tiziano Barbui
Nov 30, 2023
Share:
Learning objective: After watching this video, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

Bookmark this article

The MPN Hub invited Chloe James, University Hospital of Bordeaux, Bordeaux, FR, to give a presentation and chair a discussion on thrombotic and hemorrhagic complications in myeloproliferative neoplasms (MPN). MPN Hub Steering Committee members Jean-Jacques Kiladjian, Tiziano Barbui, and John Mascarenhas also joined the discussion.

James opens with an overview of key components of thrombosis in MPN and current treatment options. She goes on to discuss the prevention of thrombosis and concludes by discussing how to assess bleeding risk. Following this presentation, the committee members discussed this important topic area and provided further insights.

Thrombotic / hemorrhagic complications

More about...
Essential thrombocytosisMyelofibrosisMyeloproliferative neoplasmsPolycythemia vera

Related articles

Add bookmark

The role of AI in the future of MPN bone marrow histopathology

The MPN Hub invited Daniel Royston, University of Oxford, UK, to give a presentation and chair a discussion on the role of artificial intelligence in the future of MPN bone marrow...

Dec 4, 2023
Add bookmark

The role of AI in the future of MPN bone marrow histopathology

The MPN Hub invited Daniel Royston, University of Oxford, UK, to give a presentation and chair a discussion on the role of artificial...

Dec 4, 2023
Add bookmark

JAK inhibition in MPN: Updates from phase I/II trials at ASH 2022

Several exciting updates on developments in JAK inhibition for the treatment of MPN were presented at the 64th ASH Annual Meeting and Exposition. Here, we summarize key findings from...

Jan 10, 2023
Add bookmark

JAK inhibition in MPN: Updates from phase I/II trials at ASH 2022

Several exciting updates on developments in JAK inhibition for the treatment of MPN were presented at the 64th ASH Annual Meeting and...

Jan 10, 2023

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox